E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 3.17 EUR 0.32%
Market Cap: 303m EUR
Have any thoughts about
Euroapi SAS?
Write Note

EV/EBIT
Enterprise Value to EBIT

113.1
Current
74.1
Median
16.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
113.1
=
Enterprise Value
486.3m EUR
/
EBIT
4.3m EUR
All Countries
Close
Market Cap EV/EBIT
FR
Euroapi SAS
PAR:EAPI
302m EUR 113.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
747.7B USD 53.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 23.3
US
Johnson & Johnson
NYSE:JNJ
342.5B USD 14.7
US
Merck & Co Inc
NYSE:MRK
252.8B USD 12.6
CH
Roche Holding AG
SIX:ROG
216.7B CHF 12.5
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP 254.5
CH
Novartis AG
SIX:NOVN
179.3B CHF 13.5
US
Pfizer Inc
NYSE:PFE
152.2B USD 16
EBIT Growth EV/EBIT to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBIT: 1 821.6
113.1
115%
1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.6
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.5
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254.5
32%
8
CH
Novartis AG
SIX:NOVN
13.5
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-13.4
2-Years Forward
EV/EBIT
-15.5
3-Years Forward
EV/EBIT
11.1